US 8183207
Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
granted A61KA61K38/1793A61K47/60
Quick answer
US patent 8183207 (Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules) held by Five Prime Therapeutics, Inc. expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K38/1793, A61K47/60, A61K47/643, A61P